Why the study?
Does the use of type Ic antiarrhythmic drugs increase the energy required for cardioversion in patients with chronic atrial fibrillation compared to type Ia or III drugs?
Does the use of type Ic antiarrhythmic drugs increase the energy required for cardioversion in patients with chronic atrial fibrillation compared to type Ia or III drugs?
Patients taking type Ic antiarrhythmic drugs require higher energy levels for successful cardioversion of chronic atrial fibrillation compared to those on type Ia or III drugs.
Answers are grounded in this paper and cite their sources.
May require higher cardioversion energies with type Ic agents; hypothesis-generating and should not change practice without randomized confirmation.
Antiarrhythmic drugs may alter the energy for cardioversion of ventricular arrhythmias. This study compares the energy necessary for cardioverting chronic atrial fibrillation in 57 patients taking type Ia, Ic, or type III antiarrhythmic drugs. Patients taking Ia (n = 22) or III (n = 14) drugs had a median energy for cardioversion of 100 joules, while the patients taking Ic (n = 17) drugs had a median energy of 200 joules (P = 0.03). There were no differences in the frequency of unsuccessful cardioversion. There were no serious adverse events in any of the three groups, although three patients in the Ic group had greater than 3 second pauses after the shock. The data suggest that the use of Ic antiarrhythmic drugs results in a higher energy for cardioversion of atrial fibrillation. However with higher energies, conversion is as successful as for type Ia and type III.
No takes yet. Share an insight, caveat, or question.
Guarnieri et al. (1991) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: